In this video, Fool health-care bureau chief Brenton Flynn outlines the opportunities for Abbott Labs, most notably with its nutrition, pharmaceutical, and diagnostics divisions. Dietary supplements for older adults -- a growing market in the U.S. -- and pharmaceutical potential, both domestically and in emerging markets, are areas for investors to watch. However, one of Abbott's other divisions faces stiff competition and appears to be fighting significant headwinds. Find out more details in the following video.
Motley Fool Returns
Stock Advisor S&P 500
5 Years 51% 36%
17+ years 337% 93%
Stock Advisor launched in February of 2002. Returns as of 11/13/2019.Join Stock Advisor